NumFin

Accelerate Diagnostics, Inc.

Symbol: AXDX

NASDAQ

0.9248

USD

Market price today

  • -0.2405

    P/E Ratio

  • 0.0056

    PEG Ratio

  • 20.04M

    MRK Cap

  • 0.00%

    DIV Yield

Accelerate Diagnostics, Inc. (AXDX) Financial Statements

Download
AnnualQuarterly
LinearLog
On the chart you can see the default numbers in dynamics for Accelerate Diagnostics, Inc. (AXDX). Companys revenue shows the average of 3.308 M which is 1.343 % gowth. The average gross profit for the whole period is 1.461 M which is 1.435 %. The average gross profit ratio is 0.707 %. The net income growth for the company last year performance is -0.014 % which equals -1.097 % % on average for the whole company history.,

AnnualQuarterly
10Y20Y30Y40Y

Balance Sheet

Diving into the fiscal trajectory of Accelerate Diagnostics, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.518. In the realm of current assets, AXDX clocks in at 24.466 in the reporting currency. A significant portion of these assets, precisely 13.219, is held in cash and short-term investments. This segment shows a change of -0.710% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 0, if any, in the reporting currency. This indicates a difference of 0.000% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 36.102 in the reporting currency. This figure signifies a year_over_year change of -0.494%. Shareholder value, as depicted by the total shareholder equity, is valued at -19.888 in the reporting currency. The year over year change in this aspect is -0.107%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 2.622, with an inventory valuation of 3.31, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 0. Account payables and short-term debt are 4.8 and 2.29, respectively. The total debt is 39.22, with a net debt of 27.08. Other current liabilities amount to 3.41, adding to the total liabilities of 51.25. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

balance-sheet.row.cash-and-short-term-investments

96.9413.245.663.6
68.3
108.5
166.5
109.2
77.8
132.4
66.7
42
14.3
0.8
0.3
0.9
1.2
1.4
3
5.6
7.2
8.7
8.6
9.5
10.4
10.3
10.4
7.9
1.4

balance-sheet.row.short-term-investments

5.951.110.723.7
32.5
47.4
100.2
80.6
58.5
11.8
13.1
12
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

10.062.62.42.3
1.6
3.2
1.9
1.9
0
0.1
0.1
0
0.8
0.6
0.4
0
0
0
0
0.3
0.2
0
1.2
0.1
0.3
1.1
1.4
0.9
0.4

balance-sheet.row.inventory

17.243.35.25.1
9.2
8.1
7.7
8.1
0.5
1.6
0
0
0
0
0
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

13.345.321.6
1.8
1.2
0.6
0.5
0.2
0
0.3
0.1
0
0
0
0
0
0
0
0.2
0
0
0
0
0
0
0
0.2
0.2

balance-sheet.row.total-current-assets

141.9824.55673.3
82
121.9
177.6
120.5
78.4
134.2
67.1
42.1
15
1.4
0.8
0.9
1.4
1.5
3.1
6.1
7.5
8.8
9.9
9.7
11.1
11.7
12
9
2

balance-sheet.row.property-plant-equipment-net

24.445.17.87.9
9.3
11.8
7.3
4.9
4.3
5
2.5
1
0
0
0
0
0
0.1
0.2
0.2
0.2
0.1
0.1
0.1
0.2
0.3
0.3
0.2
0.1

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0.1
0.1
0.1
0.2
0.2
0.2
0.7
0
0
0
3.3
3.5
3.7
3.9
4.1
4.3
4.6
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0.1
0.1
0.1
0.2
0.2
0.2
0.7
2.8
3
3.2
3.3
3.5
3.7
3.9
4.1
4.3
4.6
0
0
0
0
0
0

balance-sheet.row.long-term-investments

0000
0
0
0
0
0
0
0
0
1.5
1.3
1.2
1.1
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

0000
8
0
0
0
0
0
0
0
0.5
0
1.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

5.151.81.21.8
-5.9
0.8
0.2
1.2
0
0
0
0
0
0.7
0
0
1.1
1
0.9
0.8
0.9
0.6
0.4
1
1.8
2.2
1.7
0.6
0.2

balance-sheet.row.total-non-current-assets

29.596.999.7
11.4
12.6
7.6
6.2
4.4
5.2
2.7
1.3
2.2
4.8
5.5
4.3
4.5
4.6
4.8
4.9
5.2
5
5.1
1.1
2
2.4
1.9
0.8
0.3

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

171.5731.46583
93.4
134.4
185.3
126.7
82.9
139.3
69.8
43.4
17.2
6.3
6.3
5.2
5.8
6.1
7.8
11
12.7
13.7
15
10.7
13.1
14.1
14
9.8
2.3

balance-sheet.row.account-payables

17.164.84.52
1.3
2.4
1.3
2.1
1
2.6
2.1
0.5
0.1
0
0
0
0.1
0.1
0.1
0.2
0.1
0.2
0.1
0.2
0.2
0.2
0.4
0.1
0.1

balance-sheet.row.short-term-debt

65.882.358.40.7
1.1
0.5
0
0
0
0
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

123.6936.119.2110.4
148.9
133.6
120.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Deferred Revenue Non Current

2.211.100
-8
0
0
0
1
1
1
0.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0.83---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

85.533.43.23.8
4.3
5.1
6.2
3.6
3
2.5
0.5
0.5
1.2
0
0
0
0
0
0
0.3
0
0
0.5
0.2
0.1
0.1
0.4
0.3
0.2

balance-sheet.row.total-non-current-liabilities

132.2239.220.7111.2
149.3
133.6
120.1
0
1
1
1
0.8
1
1.4
1.3
1.2
1.1
1.1
0.9
0.8
0.7
0.6
0.5
0.6
1.2
1.1
0.8
0.2
0.1

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

10.910.84.33
3.6
4
0
0
0
0
0.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

303.8851.387.3118.1
156.2
141.8
127.9
6.8
5
6.3
3.8
1.9
2.4
1.4
1.4
1.3
1.4
1.3
1.1
1.3
1
1
1.3
1.1
1.8
1.8
1.6
0.6
0.4

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

0.1400.10.1
0.1
0.1
0.1
0.1
0.1
0.1
0
0
23
0
0
0
0
0
0
12.9
12.9
12.5
12.3
8.2
8.3
8.4
8.5
0
0

balance-sheet.row.retained-earnings

-2598.76-668.9-607.2-570.7
-493
-414.7
-330.3
-240.8
-177.3
-110.9
-65.4
-34.5
-15.8
-10.5
-10.1
-10.8
-10
-8.4
-6.4
-3.4
-1.3
-0.4
1
1.4
2.9
3.8
3.8
0.9
-0.1

balance-sheet.row.accumulated-other-comprehensive-income-loss

-2.26-0.6-0.4-0.1
0.1
-0.1
-0.1
0.1
-0.2
0
0
0
0
0
0
0
-0.3
-0.3
-0.3
0
0
0.4
0.4
0
0
0
-0.3
0
0

balance-sheet.row.other-total-stockholders-equity

2468.57649.6585.3535.6
430
407.3
387.8
360.6
255.3
243.9
131.4
75.9
7.7
15.3
15
14.6
14.7
13.5
13.4
0.2
0.2
0.3
0.1
0
0
0
0.3
8.3
2

balance-sheet.row.total-stockholders-equity

-132.31-19.9-22.3-35.1
-62.8
-7.4
57.4
119.9
77.8
133
66
41.5
14.8
4.8
4.9
3.9
4.4
4.9
6.7
9.7
11.7
12.7
13.7
9.6
11.3
12.2
12.4
9.2
1.9

balance-sheet.row.total-liabilities-and-stockholders-equity

171.5731.46583
93.4
134.4
185.3
126.7
82.9
139.3
69.8
43.4
17.2
6.3
6.3
5.2
5.8
6.1
7.8
11
12.7
13.7
15
10.7
13.1
14.1
14
9.8
2.3

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

-132.31-19.9-22.3-35.1
-62.8
-7.4
57.4
119.9
77.8
133
66
41.5
14.8
4.8
4.9
3.9
4.4
4.9
6.7
9.7
11.7
12.7
13.7
9.6
11.3
12.2
12.4
9.2
1.9

balance-sheet.row.total-liabilities-and-total-equity

171.57---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

5.951.110.723.7
32.5
47.4
100.2
80.6
58.5
11.8
13.1
12
1.5
1.3
1.2
1.1
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-debt

190.3939.277.5111.1
150
134.1
120.1
0
0
0
0.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-debt

99.427.142.671.2
114.2
73.1
53.8
-28.5
-19.2
-120.6
-53.4
-30
-14.3
-0.8
-0.3
-0.9
-1.2
-1.4
-3
-5.6
-7.2
-8.7
-8.6
-9.5
-10.4
-10.3
-10.4
-7.9
-1.4

Cash Flow Statement

The financial landscape of Accelerate Diagnostics, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.163. The company recently extended its share capital by issuing 4, marking a difference of -85.567 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 0.29 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to 8660000.000 in the reporting currency. This is a shift of -0.303 from the previous year. In the same period, the company recorded 3.25, 0, and -10, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as -0.98, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

cash-flows.row.net-income

-54.87-61.6-62.5-77.7
-78.2
-84.3
-88.3
-64
-66.4
-45.5
-30.9
-15.3
-5.3
-0.4
0.6
-0.7
-1.7
-1.9
-3
-2.1
-1.7
-1.4
-0.4
-1.5
-0.9
0.1
2.9
1
1.1

cash-flows.row.depreciation-and-amortization

3.253.332.5
3
2.6
2.6
2.2
2.4
1.8
0.9
0.4
0.2
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.2
0.6
0.9
0.7
0.3
0.2
0.1

cash-flows.row.deferred-income-tax

0-1.20-5.6
0.5
0.4
0.1
0
0
0
0
-3.8
0
0.4
0
0
0
0
0
0
0
0
0
0
-0.4
0
0.4
0.1
-0.1

cash-flows.row.stock-based-compensation

5.395.410.622
16.5
12.6
14.7
13.9
8.8
8.4
9.6
3.8
0.8
0.1
0
0
0
0
0
0
0
0
0
0
0
0
-0.1
0
0

cash-flows.row.change-in-working-capital

4.934.92.3-0.1
-3.3
-6.1
-3.5
-8.4
1.4
0
1.4
1.3
1.5
0.5
-1.7
0
0.2
0.1
0
0.2
0.1
0.6
-0.6
-0.1
1.1
0.4
0
-0.3
-0.1

cash-flows.row.account-receivables

-0.23-0.2-0.1-0.8
1.6
-1.4
0.1
-1.9
0
0
-0.1
0.7
0.6
0.4
-1.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0.450.4-0.2-0.4
-1.4
-3.7
-4.5
-7.8
2.7
-0.4
-0.1
-0.5
0
0
0
0
0
-0.1
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

0.290.32.90.3
-1
1
-0.7
1.1
-1.2
0.3
1.3
0.2
0
2.8
0
-0.1
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

4.424.4-0.30.8
-2.6
-2.1
1.6
0.2
-0.1
0.1
0.2
0.8
0.9
-2.7
0
0
0.1
0.2
0
0.2
0.1
0
0
0
0
0
0
0
0

cash-flows.row.other-non-cash-items

1.19.1-2.111.5
11.2
10
6.8
0.6
0.4
0.2
0.3
3.9
2
-0.4
0
0.2
0.3
0
0.1
0
0.1
0.6
0.1
0.9
-0.3
-0.1
0.1
-0.1
0.1

cash-flows.row.net-cash-provided-by-operating-activities

-40.2000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-1.03-1-0.6-0.6
-1.4
-0.3
-1
-3
-2.4
-3.7
-1.9
-1.2
-0.1
-0.1
0
-0.1
-0.1
0
-0.1
-0.1
-0.1
-0.1
0
-0.1
0
0
-0.2
-0.1
0

cash-flows.row.acquisitions-net

000.60.6
1.4
0.3
1
-8.6
-7.3
1.1
1.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

00-27.5-30.1
-46.9
-50.2
-120.6
-82.3
-74.1
-12.4
-7.7
-12
-0.1
-0.1
-0.1
0
0
0
0
-0.1
0
-0.1
-0.1
-0.1
0
-0.1
-0.1
0
0

cash-flows.row.sales-maturities-of-investments

9.79.740.539
61.9
103.4
101.4
59.6
26.9
13.4
6.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

8.220-0.6-0.6
-1.4
-0.3
-1
8.6
7.3
-1.1
-1.9
0
0
0
0
-0.1
0
-0.1
0.2
0.1
-0.1
0
-0.1
-0.5
-0.2
-0.9
-1.1
-0.6
-0.1

cash-flows.row.net-cash-used-for-investing-activites

8.668.712.48.3
13.6
52.8
-20.1
-25.7
-49.6
-2.7
-3.4
-13.2
-0.2
-0.2
-0.1
-0.1
-0.1
-0.1
0.1
-0.1
-0.3
-0.2
-0.2
-0.7
-0.3
-1
-1.4
-0.7
-0.1

cash-flows.row.debt-repayment

-1.46-10-1.3-0.4
-0.4
0
0
0
0
-0.1
-0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

32.85433.143.2
0.4
1.5
0.6
83.8
0.2
104.2
44.9
19.9
14.4
0
0.3
0
0.9
0
0
0
0
0.1
0
0
0
0
0.3
6.2
0

cash-flows.row.common-stock-repurchased

000.20.3
0
0
-45.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.1
-0.1
-0.1
-0.2
0
0
0

cash-flows.row.dividends-paid

000-0.3
0
0
0
0
0
0
0
0
0
-6.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

-23.96-1-0.40.4
11.6
5.4
170.3
6.6
1.5
0.8
0.9
21
0.1
6.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-cash-used-provided-by-financing-activities

9.02931.643.2
11.6
6.8
125.8
90.4
1.8
104.8
45.7
40.9
14.5
0.2
0.3
0
0.9
0
0
0
0
0.1
-0.1
-0.1
-0.1
-0.2
0.3
6.2
0

cash-flows.row.effect-of-forex-changes-on-cash

-0.25-0.3-0.3-0.1
-0.1
-0.1
-0.1
0.3
-0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-7.8
0

cash-flows.row.net-change-in-cash

-22.77-22.8-54.1
-25.2
-5.2
37.7
9.3
-101.3
67
23.5
18
13.5
0.5
-0.6
-0.4
-0.2
-1.6
-2.6
-1.7
-1.5
0.1
-0.9
-0.8
0.1
-0.2
2.6
-1.4
1

cash-flows.row.cash-at-end-of-period

90.9912.134.939.9
35.8
61
66.3
28.5
19.2
120.6
53.6
30
14.3
0.8
0.3
0.9
1.2
1.4
3
5.6
7.2
8.7
8.6
9.5
10.4
10.3
10.4
0
1.4

cash-flows.row.cash-at-beginning-of-period

113.7634.939.935.8
61
66.3
28.5
19.2
120.6
53.6
30
12.1
0.8
0.3
0.9
1.2
1.4
3
5.6
7.2
8.7
8.6
9.5
10.4
10.3
10.4
7.9
1.4
0.4

cash-flows.row.operating-cash-flow

-40.2-40.2-48.7-47.3
-50.4
-64.8
-67.8
-55.7
-53.4
-35.1
-18.8
-9.7
-0.8
0.4
-0.8
-0.2
-1
-1.5
-2.6
-1.6
-1.2
0.2
-0.7
-0.1
0.4
1
3.7
0.9
1.1

cash-flows.row.capital-expenditure

-1.03-1-0.6-0.6
-1.4
-0.3
-1
-3
-2.4
-3.7
-1.9
-1.2
-0.1
-0.1
0
-0.1
-0.1
0
-0.1
-0.1
-0.1
-0.1
0
-0.1
0
0
-0.2
-0.1
0

cash-flows.row.free-cash-flow

-41.23-41.2-49.3-47.9
-51.8
-65.1
-68.8
-58.7
-55.8
-38.8
-20.7
-10.9
-0.9
0.4
-0.8
-0.3
-1.1
-1.5
-2.7
-1.7
-1.3
0
-0.7
-0.1
0.4
1
3.5
0.8
1.1

Income Statement Row

Accelerate Diagnostics, Inc.'s revenue saw a change of -0.054% compared with the previous period. The gross profit of AXDX is reported to be 2.55. The company's operating expenses are 56.58, showing a change of -14.416% from the last year. The expenses for depreciation and amortization are 3.25, which is a -0.021% change from the last accounting period. Operating expenses are reported to be 56.58, which shows a -14.416% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.140% year-over-year growth. The operating income is -54.03, which shows a -0.140% change when compared to the previous year. The change in the net income is -0.014%. The net income for the last year was -61.62.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

income-statement-row.row.total-revenue

12.0312.112.811.8
11.2
9.3
5.7
4.2
0.2
0.1
0.1
0
0.2
1.1
2.2
1.3
0.5
0.2
0.2
0.5
0.1
0.9
0.7
0.9
1.6
2.9
7.4
2.5
2.1

income-statement-row.row.cost-of-revenue

9.519.59.412.2
6.7
4.9
3.2
1
0
0
0
0
0
0
0
0
0
0.1
0
0.2
0.1
0.1
0.2
0.5
0.6
1.2
1.2
0.3
0.3

income-statement-row.row.gross-profit

2.522.53.3-0.4
4.5
4.4
2.5
3.2
0.2
0.1
0.1
0
0.2
1.1
2.2
1.3
0.5
0.1
0.2
0.3
0.1
0.7
0.5
0.3
0.9
1.7
6.2
2.2
1.8

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

25.38---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0.0413.1-0.20
-0.1
0
0
-0.2
2.4
1.8
0.9
0
0.2
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.5
0.2
0.6
0.9
0
0
0.2
0.1

income-statement-row.row.operating-expenses

56.6156.666.171.2
68.2
77.2
82.9
67.4
66.7
45.7
31.6
15.3
3.6
1.5
1.6
1.9
2.2
2.2
3.4
2.6
1.8
2.2
1.2
1.8
3.2
2.2
2.3
1.4
0.6

income-statement-row.row.cost-and-expenses

63.7366.175.683.3
74.9
82.1
86
68.4
66.7
45.7
31.6
15.3
3.6
1.5
1.6
1.9
2.2
2.3
3.4
2.8
1.9
2.4
1.4
2.3
3.9
3.4
3.5
1.7
0.9

income-statement-row.row.interest-income

1.121.10.60.1
0.9
2.8
2.8
0.9
0.5
0.1
0.1
0
0
0
0
0
0
0
0
0
0.1
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

7.747.73.815.5
15.6
14.3
10.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

13.8-6.70.2-6.1
-14.5
-11.6
-0.5
-0.3
-0.1
0.1
0
0
-2
0
0
-0.1
0
0.1
0
0
0
-0.1
-0.1
-1
0.3
0.6
0.5
0.3
-1.2

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0.0413.1-0.20
-0.1
0
0
-0.2
2.4
1.8
0.9
0
0.2
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.5
0.2
0.6
0.9
0
0
0.2
0.1

income-statement-row.row.total-operating-expenses

13.8-6.70.2-6.1
-14.5
-11.6
-0.5
-0.3
-0.1
0.1
0
0
-2
0
0
-0.1
0
0.1
0
0
0
-0.1
-0.1
-1
0.3
0.6
0.5
0.3
-1.2

income-statement-row.row.interest-expense

7.747.73.815.5
15.6
14.3
10.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

3.723.33.32.6
3.8
5.4
2.6
2.2
2.4
1.8
0.9
0.4
0.2
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.2
0.6
0.9
0.7
0.3
0.2
0.1

income-statement-row.row.ebitda-caps

-47.47---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-51.7-54-62.8-71.6
-63.7
-72.8
-80.4
-64.2
-66.5
-45.5
-31.5
-15.3
-5.4
-0.4
0.6
-0.7
-1.7
-2.1
-3.2
-2.3
-1.8
-1.5
-0.8
-1.4
-2.3
-0.5
3.9
0.8
1.2

income-statement-row.row.income-before-tax

-54.01-60.8-62.6-77.7
-78.2
-84.4
-88.1
-63.5
-66.1
-45.5
-31.5
-15.3
-5.3
-0.4
0.6
-0.7
-1.7
-1.9
-3
-2.1
-1.7
-1.4
-0.7
-1.9
-1.5
0
4.4
1.2
1.1

income-statement-row.row.income-tax-expense

20.8-0.10
0
-0.1
0.2
-0.7
0.3
0.1
-0.5
0
2
0.4
-0.6
0.7
0
-0.2
-0.2
-0.2
-0.8
0
-0.3
-0.3
-0.5
0
1.6
0.2
-1.1

income-statement-row.row.net-income

-56.02-61.6-62.5-77.7
-78.2
-84.3
-88.3
-62.9
-66.4
-45.5
-30.9
-15.3
-5.3
-0.4
0.6
-0.7
-1.7
-1.9
-3
-2.1
-0.9
-1.4
-0.4
-1.5
-0.9
0.1
2.9
1
1.1
Similar Stocks
You may also be interested in:
EW
Edwards Lifesciences Corporation.
85.25 USD
NYSE
SOFW.TA
SofWave Medical Ltd..
1748 ILA
TLV
4549.T
Eiken Chemical Co., Ltd..
2002 JPY
JPX
688580.SS
Nanjing Vishee Medical Technology Co., Ltd.
45.89 CNY
SHH
USAQ
QHSLab, Inc..
0.08685 USD
PNK
QLIFE.ST
Qlife Holding AB (publ).
0.003 SEK
STO
VITR.ST
Vitrolife AB (publ).
175.2 SEK
STO
LFWD
ReWalk Robotics Ltd..
4.87 USD
NASDAQ
BBLG
Bone Biologics Corporation.
1.85 USD
NASDAQ
300298.SZ
Sinocare Inc..
23.89 CNY
SHZ
HYPR
Hyperfine, Inc..
0.8 USD
NASDAQ

Frequently Asked Question

What is Accelerate Diagnostics, Inc. (AXDX) total assets?

Accelerate Diagnostics, Inc. (AXDX) total assets is 31366000.000.

What is enterprise annual revenue?

The annual revenue is 6299000.000.

What is firm profit margin?

Firm profit margin is 0.210.

What is company free cash flow?

The free cash flow is -2.830.

What is enterprise net profit margin?

The net profit margin is -4.656.

What is firm total revenue?

The total revenue is -4.297.

What is Accelerate Diagnostics, Inc. (AXDX) net profit (net income)?

The net profit (net income) is -61618000.000.

What is firm total debt?

The total debt is 39220000.000.

What is operating expences number?

The operating expences are 56578000.000.

What is company cash figure?

Enretprise cash is 12138000.000.